Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119422567 | 11942256 | 7 | F | 20150609 | 20160816 | 20160125 | 20160823 | EXP | CA-ROCHE-1698074 | ROCHE | 60.99 | YR | M | Y | 0.00000 | 20160824 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119422567 | 11942256 | 1 | PS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0062,S0068D,S0003B | 103976 | 375 | MG | SOLUTION FOR INJECTION | QOW | |||||
| 119422567 | 11942256 | 2 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0062,S0068D,S0003B | 103976 | SOLUTION FOR INJECTION | |||||||
| 119422567 | 11942256 | 3 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0062,S0068D,S0003B | 103976 | SOLUTION FOR INJECTION | |||||||
| 119422567 | 11942256 | 4 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0062,S0068D,S0003B | 103976 | SOLUTION FOR INJECTION | |||||||
| 119422567 | 11942256 | 5 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | U | S0062,S0068D,S0003B | 103976 | 375 | MG | SOLUTION FOR INJECTION | QOW | |||||
| 119422567 | 11942256 | 6 | C | ADVAIR HFA | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Unknown | UNK | U | 0 | |||||||||
| 119422567 | 11942256 | 7 | C | SINGULAIR | MONTELUKAST SODIUM | 1 | Unknown | UNK | U | 0 | |||||||||
| 119422567 | 11942256 | 8 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | Unknown | U | 0 | ||||||||||
| 119422567 | 11942256 | 9 | C | VENTOLIN | ALBUTEROL SULFATE | 1 | Unknown | UNK | U | 0 | |||||||||
| 119422567 | 11942256 | 10 | C | RAMIPRIL. | RAMIPRIL | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 119422567 | 11942256 | 1 | Asthma |
| 119422567 | 11942256 | 6 | Product used for unknown indication |
| 119422567 | 11942256 | 7 | Product used for unknown indication |
| 119422567 | 11942256 | 8 | Product used for unknown indication |
| 119422567 | 11942256 | 9 | Product used for unknown indication |
| 119422567 | 11942256 | 10 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 119422567 | 11942256 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 119422567 | 11942256 | Blood pressure increased | |
| 119422567 | 11942256 | Deafness unilateral | |
| 119422567 | 11942256 | Drug ineffective | |
| 119422567 | 11942256 | Ear infection | |
| 119422567 | 11942256 | Fatigue | |
| 119422567 | 11942256 | Lung disorder | |
| 119422567 | 11942256 | Nasal congestion | |
| 119422567 | 11942256 | Psoriasis | |
| 119422567 | 11942256 | Pulmonary congestion | |
| 119422567 | 11942256 | Urticaria |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 119422567 | 11942256 | 1 | 20150609 | 0 | ||
| 119422567 | 11942256 | 2 | 20160303 | 0 | ||
| 119422567 | 11942256 | 3 | 20160512 | 0 | ||
| 119422567 | 11942256 | 4 | 20160707 | 0 | ||
| 119422567 | 11942256 | 5 | 20160721 | 20160721 | 0 |